Butrans

Butrans is a brand name of buprenorphine, approved by the FDA in the following formulation(s):

BUTRANS (buprenorphine - film, extended release; transdermal)

• 
  Manufacturer: PURDUE PHARMA LP
  
  Approval date: June 30, 2010
  
  Strength(s): 10MCG/HR, 20MCG/HR ^[RLD], 5MCG/HR
  

Has a generic version of Butrans been approved?

No. There is currently no therapeutically equivalent version of Butrans available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Butrans. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Transdermal resorption of active substances from supercooled masses of levulic acid
  Patent 6,264,980
  Issued: July 24, 2001
  Inventor(s): Hille; Thomas
  Assignee(s): LTS Lohmann Therapie-Systeme GmbH
  A pharmaceutical product for the release of medicinal agents to the skin having absorption-increasing auxiliary agents is characterized in that the auxiliary material forms subcooled melts.
  
  Patent expiration dates:
  
  
  • December 18, 2015
    
    ✓ 
    Drug product
  
  



• 
  Transdermal absorption of active substances from subcooled melts
  Patent 6,344,211
  Issued: February 5, 2002
  Inventor(s): Thomas; Hille
  Assignee(s): LTS Lohmann Therapie-Systeme GmbH
  A pharmaceutical product for the release of medicinal agents to the skin having absorption-increasing auxiliary agents is characterized in that the auxiliary material forms subcooled melts.
  
  Patent expiration dates:
  
  
  • December 18, 2015
    
    ✓ 
    Patent use: THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
  
  



• 
  Method of providing sustained analgesia with buprenorpine
  Patent RE41408
  Issued: June 29, 2010
  Inventor(s): Reder; Robert F. & Kaiko; Robert F. & Goldenheim; Paul D.
  Assignee(s): Purdue Pharma L.P.
  A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
  
  Patent expiration dates:
  
  
  • September 29, 2017
    
    ✓ 
    Patent use: THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
  
  



• 
  Method of providing sustained analgesia with buprenorphine
  Patent RE41489
  Issued: August 10, 2010
  Inventor(s): Reder; Robert F. & Kaiko; Robert F. & Goldenheim; Paul D.
  Assignee(s): Purdue Pharma L.P.
  A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
  
  Patent expiration dates:
  
  
  • September 29, 2017
    
    ✓ 
    Patent use: THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
  
  



• 
  Method of providing sustained analgesia with buprenorphine
  Patent RE41571
  Issued: August 24, 2010
  Inventor(s): Reder; Robert F. & Kaiko; Robert F. & Goldenheim; Paul D.
  Assignee(s): Purdue Pharma L.P.
  A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
  
  Patent expiration dates:
  
  
  • September 29, 2017
    
    ✓ 
    Patent use: THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 30, 2013 - NEW DOSAGE FORM
  
  

See also...

• Butrans Consumer Information (Drugs.com)
• Butrans Patch Consumer Information (Wolters Kluwer)
• Butrans transdermal Consumer Information (Cerner Multum)
• Butrans Advanced Consumer Information (Micromedex)
• Buprenorphine Consumer Information (Wolters Kluwer)
• Buprenorphine Patch Consumer Information (Wolters Kluwer)
• Buprenorphine Tablets Consumer Information (Wolters Kluwer)
• Buprenorphine Consumer Information (Cerner Multum)
• Buprenorphine injection Consumer Information (Cerner Multum)
• Buprenorphine transdermal Consumer Information (Cerner Multum)
• Buprenorphine Injection Advanced Consumer Information (Micromedex)
• Buprenorphine Sublingual Advanced Consumer Information (Micromedex)
• Buprenorphine Transdermal Advanced Consumer Information (Micromedex)
• Buprenorphine Hydrochloride AHFS DI Monographs (ASHP)